With Targets from LLNL, Phylos Will Make Hundreds of Binding Proteins Per Quarter | GenomeWeb

Joanna Albala, a senior biomedical scientist at Lawrence Livermore National Lab, said her lab’s new partnership with proteomics company Phylos is the outcome of “a true networking opportunity” at last year’s Chips to Hits meeting in Philadelphia. It was there that executives from Phylos, a Lexington, Mass., developer of protein binders, happened to be on the lookout for a collaborator that could custom deliver target proteins. Albala sat down next to one of them during a luncheon in the exhibit hall.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.